Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers
PET scan
Laminopatías+5
+ Enfermedades Cardiovasculares
+ Enfermedades del Corazón
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de enero de 1994
Fecha en la que se inscribió al primer participante.Deterioration in left ventricular function, which is characteristic in patients with congestive heart failure, appears to be a multifactorial process. Beta-blockers appear to reverse the deterioration and frequently improve left ventricular function in patients with both ischemic and non-ischemic cardiomyopathies. The mechanism by which beta-blockers improve ejection fraction is not known. Although it is well established that regional flow, function and metabolism may improve after coronary revascularization whether beta-blocker therapy will have similar salutary results in patients with congestive heart failure is unknown. The aim of this study is to: 1) quantitate regional glucose uptake and regional blood flow before and after chronic beta-blocker administration to patients with congestive heart failure using positron emission tomography, 2) determine if alteration in either regional glucose or lipid uptake or regional blood flow correlate with improvement in wall motion and global left ventricular function, and 3) determine if ischemic and nonischemic myocardium differ in blood flow or metabolism.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 130 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%. New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment. Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel. Dilated cardiomyopathy-if no coronary disease. No pregnant or lactating women. No women of child-bearing age not on proven birth control. No severe hepatic or renal disease. No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl. No primary valvular heart disease. No PTCA or CABG within 3 months of enrollment. No history of myocardial infarction or unstable angina within past 2 months. No resting heart rate less than 60 bpm. No A-V block greater than 1 degree block without pacemaker. No severe ETOH abuse within 6 months of enrollment. No severe bronchospasm.
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene una ubicación
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, United StatesAbrir National Heart, Lung and Blood Institute (NHLBI) en Google Maps